State Street Holds 4.3% Of Viridian Therapeutics As Drugmaker Begins Commercial Sales

The September-end holding totaled 4,876,395 shares; Viridian reported $24.7 million from Lumvoa's first quarter on the market.

Share
State Street Holds 4.3% Of Viridian Therapeutics As Drugmaker Begins Commercial Sales

State Street held a 4.3% passive stake in Viridian Therapeutics, which develops medicines for serious and rare diseases, according to an SEC ownership disclosure filed Tuesday. The 4,876,395-share position was measured as of September 30, rather than the filing day, and comes as Viridian begins generating commercial drug revenue.

September Ownership, Not Tuesday Buying

State Street reported shared authority to sell or otherwise dispose of the entire holding. Its shared voting authority covered 4,633,744 shares, with no sole voting authority.

State Street certified that the shares were bought and held as part of its ordinary business, rather than with the aim or effect of changing Viridian's control. The disclosure describes a passive position in the common-stock class, not a campaign to direct the company.

Lumvoa Starts Bringing In Revenue

Viridian reported $24.7 million in Lumvoa net product revenue on Wednesday's earnings call, covering the drug's first quarter on the market. More than 100 patients had started treatment by quarter end.

The company said its cash and securities balance of just over $955 million funds its current plans through profitability. Viridian's market value was $3.4 billion in Tuesday trading, as of 10:22 a.m. ET.

Viridian focuses on autoimmune conditions, particularly thyroid eye disease, which inflames tissue surrounding the eye. Its work includes medicines delivered by intravenous infusion and injections under the skin, alongside experimental treatments for other autoimmune disorders. Commercial sales now sit alongside that development work.

VRDN-008 Heads Toward Patient Trials

Viridian announced positive early-stage results Monday for VRDN-008 in healthy volunteers. President and CEO Steve Mahoney described the findings as an important clinical step for patients with autoimmune diseases caused by antibodies that attack the body's own tissues; that assessment rested on the early study.

Viridian plans to begin a VRDN-008 trial in myasthenia gravis in mid-2027, pending regulatory feedback, as part of its plan to start at least one pivotal trial in 2027.

Sources

More on Viridian Therapeutics

All Viridian Therapeutics (VRDN) coverage →